menu
    • menu
    [{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allgenesis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Lexitas","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Lexitas","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Lexitas"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"AffaMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"AG-73305","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allgenesis Biotherapeutics \/ Allgenesis Biotherapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Allgenesis Biotherapeutics \/ Allgenesis Biotherapeutics"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Ora, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Ora, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis Biotherapeutics \/ Ora, Inc"},{"orgOrder":0,"company":"Allgenesis Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AG-80308","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Allgenesis Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Allgenesis Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allgenesis Biotherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Allgenesis Biotherapeutics

    Menu

    Allgenesis Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-80308

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and S...

                            Details : AG-80308 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of inflammation associated with Dry Eye Disease (DED).

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            June 19, 2023

                            Lead Product(s) : AG-80308

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Recipient : AffaMed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data fro...

                            Details : AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases and contains a VEGF-trap and a disintegrin that blocks various key integrin recept...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2023

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Recipient : AffaMed Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the...

                            Details : AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases and contains a VEGF-trap and a disintegrin that blocks various key integrin recept...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-80308

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of AG-80308 in Dry Eye Patients

                            Details : AG-80308 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 12, 2022

                            Lead Product(s) : AG-80308

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Ora, Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Lexitas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AG-73305 Single Ascending Dose Cohort Study in DME

                            Details : AG-73305 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Macular Edema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2022

                            Lead Product(s) : AG-73305

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Lexitas

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed

                            Allgenesis Biotherapeutics

                            Taiwan arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AG-86893

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia

                            Details : AG-86893 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pterygium.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 23, 2018

                            Lead Product(s) : AG-86893

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth